Share on StockTwits
 

Needham & Company raised their price objective on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from $65.00 to $84.00 in a research note issued on Friday, StockRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. Needham & Company’s price target points to a potential upside of 2.99% from the company’s current price.

Several other analysts have also recently commented on the stock. Analysts at JMP Securities raised their price target on shares of Alnylam Pharmaceuticals from $68.00 to $110.00 in a research note on Friday, January 31st. Separately, analysts at Deutsche Bank raised their price target on shares of Alnylam Pharmaceuticals from $80.00 to $108.00 in a research note on Friday, January 17th. They now have a “buy” rating on the stock. Finally, analysts at Morgan Stanley downgraded shares of Alnylam Pharmaceuticals from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 14th. They now have a $54.00 price target on the stock, down previously from $72.00. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $77.50.

Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 5.53% during mid-day trading on Friday, hitting $77.0499. 308,693 shares of the company’s stock traded hands. Alnylam Pharmaceuticals has a 1-year low of $21.60 and a 1-year high of $112.57. The stock has a 50-day moving average of $77.44 and a 200-day moving average of $61.69. The company’s market cap is $4.887 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Wednesday, February 19th. The company reported ($0.51) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.45) by $0.06. The company had revenue of $10.80 million for the quarter, compared to the consensus estimate of $9.98 million. During the same quarter last year, the company posted ($1.20) earnings per share. Alnylam Pharmaceuticals’s revenue was up 27.1% compared to the same quarter last year. On average, analysts predict that Alnylam Pharmaceuticals will post $-1.77 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.